Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.

Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. doi: 10.1158/1055-9965.EPI-13-0349. Epub 2013 Aug 27.

2.

Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.

Breen KJ, O'Neill A, Murphy L, Fan Y, Boyce S, Fitzgerald N, Dorris E, Brady L, Finn SP, Hayes BD, Treacy A, Barrett C, Aziz MA, Kay EW, Fitzpatrick JM, Watson RWG.

Prostate. 2017 Sep;77(12):1288-1300. doi: 10.1002/pros.23389. Epub 2017 Jul 20.

PMID:
28726241
3.

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL.

J Natl Cancer Inst. 2015 Nov 27;108(2). pii: djv346. doi: 10.1093/jnci/djv346. Print 2016 Feb.

4.

Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer.

Iqbal J, Thike AA, Cheok PY, Tse GM, Tan PH.

Histopathology. 2012 Oct;61(4):652-9. doi: 10.1111/j.1365-2559.2012.04255.x.

PMID:
22759273
5.

Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.

Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V.

Anticancer Res. 2003 Sep-Oct;23(5A):3825-35.

PMID:
14666684
6.

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z; Transatlantic Prostate Group.

Br J Cancer. 2013 Jun 25;108(12):2582-9. doi: 10.1038/bjc.2013.248. Epub 2013 May 21.

7.

Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer.

Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA, Netto GJ.

Mod Pathol. 2012 Nov;25(11):1543-9. doi: 10.1038/modpathol.2012.104. Epub 2012 Jun 8.

8.

SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.

Huang KC, Bégin LR, Palanisamy N, Donnelly B, Bismar TA.

Urol Oncol. 2016 May;34(5):235.e1-10. doi: 10.1016/j.urolonc.2015.11.015. Epub 2015 Dec 22.

PMID:
26725250
9.

Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.

Al Bashir S, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA.

J Hematol Oncol. 2014 Mar 7;7:21. doi: 10.1186/1756-8722-7-21.

10.

Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.

Murphy SJ, Karnes RJ, Kosari F, Castellar BE, Kipp BR, Johnson SH, Terra S, Harris FR, Halling GC, Klein JL, Nasir A, Bergstrahl E, Rangel LJ, Sukov WR, Vasmatzis G, Cheville JC.

Mod Pathol. 2016 Feb;29(2):143-56. doi: 10.1038/modpathol.2015.136. Epub 2015 Nov 27.

11.

High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki JR, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Mod Pathol. 2014 Jan;27(1):96-106. doi: 10.1038/modpathol.2013.127. Epub 2013 Jul 26.

12.

PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells.

Zhao H, Dupont J, Yakar S, Karas M, LeRoith D.

Oncogene. 2004 Jan 22;23(3):786-94.

PMID:
14737113
13.

VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.

Goel HL, Chang C, Pursell B, Leav I, Lyle S, Xi HS, Hsieh CC, Adisetiyo H, Roy-Burman P, Coleman IM, Nelson PS, Vessella RL, Davis RJ, Plymate SR, Mercurio AM.

Cancer Discov. 2012 Oct;2(10):906-21. doi: 10.1158/2159-8290.CD-12-0085. Epub 2012 Jul 9.

14.

Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade.

Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, Angel P, Mayer D.

Hum Pathol. 2005 Nov;36(11):1186-96. Epub 2005 Oct 7.

PMID:
16260272
15.

βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.

Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S, Quaas A.

Am J Pathol. 2014 Mar;184(3):609-17. doi: 10.1016/j.ajpath.2013.11.007. Epub 2013 Dec 28.

PMID:
24378408
16.

Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease.

Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM.

Cancer Res. 2002 May 15;62(10):2942-50.

17.

Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer.

Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D.

Int J Cancer. 2000 Nov 20;89(6):506-13.

18.

A HIF-1alpha-dependent autocrine feedback loop promotes survival of serum-deprived prostate cancer cells.

Thomas R, Kim MH.

Prostate. 2009 Feb 15;69(3):263-75. doi: 10.1002/pros.20885.

PMID:
19016246
19.

Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis.

Schmitz M, Grignard G, Margue C, Dippel W, Capesius C, Mossong J, Nathan M, Giacchi S, Scheiden R, Kieffer N.

Int J Cancer. 2007 Mar 15;120(6):1284-92.

20.

A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer.

Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker A, Pollak M.

Clin Cancer Res. 2012 Jun 15;18(12):3407-13. doi: 10.1158/1078-0432.CCR-12-0482. Epub 2012 May 2.

Supplemental Content

Support Center